⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
Hagens Berman Sobol Shapiro LLP and Lowey Dannenberg, P.C. Announce Certification of a Class of Third Party Payors Who Purchased or Paid for Some or All of the Price of Stelara
prnewswire.com
JNJ
Johnson & Johnson to Participate in the 44 th Annual J.P. Morgan Healthcare Conference
businesswire.com
JNJ
Eczema Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AMGN
PFE
LLY
AZN
BMY
NVS
SNY
GSK
UCB
ARQT
REGN
INCY
ABBV
BIIB
MRK
JNJ
VNDA
RAPT
CHAI
ONON
ION
ASMB
CRVS
APG
KSCP
KYMR
XBI
IBB
ADSK
CDNS
SNPS
Global Demand Spurs Competition in CAR T-Cell Therapy for Multiple Myeloma
globenewswire.com
BMY
JNJ
NVS
GILD
Die frühere Anwendung von CARVYKTI®▼ (ciltacabtagene autoleucel) führte bei Patienten mit rezidiviertem oder refraktärem Multiplem Myelom nach 2,5 Jahren zu einer anhaltenden, behandlungsfreien Remission
globenewswire.com
JNJ
LGND
MIKEWORLDWIDE APPOINTS ABRAHAM ESPINOSA AS EXECUTIVE VICE PRESIDENT OF STRATEGY
prnewswire.com
JNJ
PEP
VZ
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
prnewswire.com
JNJ
Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
globenewswire.com
JNJ
LGND
Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC
prnewswire.com
JNJ
K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appointment of Dr. Shinta Cheng, M.D., Ph.D., as Chief
prnewswire.com
SWX
JNJ
BMY